Emerging Therapies for Patients with Atopic Dermatitis
214492144921449
It’s an exciting time for new therapies in atopic dermatitis with several therapies recently approved or in late-stage development. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Baltimore dermatologist Dr. Shawn Kwatra, who outlined the new treatment options. From therapies that target IL-13 and IL-31 to JAK inhibitors, dermatology cl …
It’s an exciting time for new therapies in atopic dermatitis with several therapies recently approved or in late-stage development. Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Baltimore dermatologist Dr. Shawn Kwatra, who outlined the new treatment options. From therapies that target IL-13 and IL-31 to JAK inhibitors, dermatology cl … Continue reading "Emerging Therapies for Patients with Atopic Dermatitis"
Roflumilast is a non-steroidal topical cream that was FDA approved for the treatment of plaque psoriasis in 2022.1 Roflumilast selectively inhibits phosphodiesterase-4 (PDE-4), which is an enzyme that mediates inflammatory responses and has been shown to play a role in several dermatologic diseases.2 Prior to topical roflumilast, oral PDE-4 inhibitors have been investigated across a wide variety o … 
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic & Surgical Conference, interviewed Dr. George Han, associate professor of dermatology at the Donald and Barbara Zucker School of Medicine at Hofstra/Northwell. Dr. Han shares why it’s an exciting time to treat psoriasis, and why the developments of the past year have bolstered the clinician’s armamentarium. Watch and lear … 